Novo Nordisk - 40 Year Stock Price History | NVO

Historical daily share price chart and data for Novo Nordisk since 1982 adjusted for splits. The latest closing stock price for Novo Nordisk as of August 18, 2022 is 102.76.
  • The all-time high Novo Nordisk stock closing price was 121.15 on April 07, 2022.
  • The Novo Nordisk 52-week high stock price is 122.16, which is 18.9% above the current share price.
  • The Novo Nordisk 52-week low stock price is 91.51, which is 10.9% below the current share price.
  • The average Novo Nordisk stock price for the last 52 weeks is 106.99.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novo Nordisk Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 106.6296 107.1738 121.1523 91.7169 102.7600 -6.87%
2021 86.9122 69.0563 115.3407 64.8316 110.3362 63.39%
2020 62.2051 55.2182 71.3476 46.7973 67.5289 23.31%
2019 48.1537 43.8892 55.1236 43.4859 54.7641 26.73%
2018 44.8258 49.4896 53.1264 38.9647 43.2139 -11.88%
2017 38.7770 31.8392 49.0967 29.2332 49.0419 54.29%
2016 42.5876 49.4320 50.4837 27.9834 31.7860 -36.56%
2015 46.1536 36.1088 51.9597 35.6074 50.1049 39.32%
2014 37.5745 30.6277 41.6666 30.6277 35.9643 16.69%
2013 28.3800 27.1343 31.7832 25.1130 30.8196 15.44%
2012 24.0041 18.8006 27.8262 18.5595 26.6975 44.10%
2011 18.5319 17.6133 21.1266 15.2032 18.5274 3.90%
2010 13.5907 10.2144 17.8319 10.0137 17.8319 79.47%
2009 8.7255 8.0392 10.7886 6.5311 9.9359 27.03%
2008 9.1391 9.5870 11.1152 6.6998 7.8216 -19.75%
2007 7.9748 6.1811 10.2256 6.0914 9.7462 57.36%
2006 4.9656 4.1463 6.2470 3.9999 6.1936 51.05%
2005 3.8664 3.8052 4.3627 3.5336 4.1004 5.25%
2004 3.5253 2.9137 3.9495 2.7689 3.8957 34.62%
2003 2.4576 2.0451 2.8939 1.7634 2.8939 43.95%
2002 2.2005 2.7628 2.8242 1.5519 2.0103 -27.24%
2001 2.7722 2.4317 3.1851 2.3907 2.7628 14.18%
2000 2.3478 1.8265 3.0785 1.6823 2.4196 37.84%
1999 1.5734 1.8822 1.8822 1.3012 1.7554 -1.99%
1998 1.8866 1.9118 2.2795 1.4580 1.7911 -7.46%
1997 1.4382 1.2018 1.9386 1.1751 1.9354 55.02%
1996 0.9869 0.9296 1.2651 0.8464 1.2485 37.24%
1995 0.7368 0.6162 0.9097 0.5965 0.9097 45.32%
1994 0.6569 0.6492 0.7248 0.5799 0.6260 -3.57%
1993 0.5843 0.5751 0.6492 0.5115 0.6492 12.24%
1992 0.5735 0.5875 0.6273 0.5179 0.5784 -0.17%
1991 0.4539 0.3999 0.5989 0.3661 0.5794 44.63%
1990 0.3304 0.3158 0.4119 0.2834 0.4006 25.90%
1989 0.2794 0.2433 0.3301 0.2433 0.3182 30.79%
1988 0.2033 0.1426 0.2622 0.1426 0.2433 84.60%
1987 0.2061 0.2021 0.2554 0.1241 0.1318 -34.30%
1986 0.1876 0.1751 0.2098 0.1608 0.2006 13.08%
1985 0.1699 0.1434 0.2098 0.1397 0.1774 23.71%
1984 0.2525 0.3420 0.3691 0.1298 0.1434 -57.60%
1983 0.3534 0.2559 0.4393 0.2559 0.3382 27.67%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $237.182B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $440.598B 16.77
Eli Lilly (LLY) United States $301.034B 38.17
Pfizer (PFE) United States $276.521B 8.10
AbbVie (ABBV) United States $250.080B 10.63
Merck (MRK) United States $230.630B 12.04
Novartis AG (NVS) Switzerland $188.558B 13.90